Wikidata

(Q40406835)

English

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

scientific article published on 8 July 2005

In more languages

Statements

title
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
16006586
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16006586%20AND%20SRC:MED&resulttype=core&format=json
retrieved
30 December 2019
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q40406835&oldid=1646943764"